Thrombosis and Drug-Eluting Stents. An Objective Appraisal

Journal of the American College of Cardiology

Volumn 50, Issue 2, 2007, Pages 109-118

  Holmes Jr , David R ^a   Kereiakes, Dean J ^b   Laskey, Warren K ^c   Colombo, Antonio ^d   Ellis, Stephen G ^e   Henry, Timothy D ^f   Popma, Jeffrey J ^g   Serruys, Patrick W J C ^h   Kimura, Takeshi ⁱ   Williams, David O ^j   Windecker, Stephan ^k   Krucoff, Mitchell W ^l  

^a MAYO CLINIC   (United States)

^b The Carl & Edyth Lindner Center for Research & Education   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e LERNER RESEARCH INSTITUTE   (United States)

^f MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ KYOTO UNIVERSITY   (Japan)

^j RHODE ISLAND HOSPITAL   (United States)

^k UNIVERSITY OF BERN   (Switzerland)

^l DUKE CLINICAL RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; LOW MOLECULAR WEIGHT HEPARIN; PACLITAXEL; RAPAMYCIN; THIENOPYRIDINE; UNCLASSIFIED DRUG;

ANGIOCARDIOGRAPHY; ANGIOGRAPHY; BLEEDING; BLOOD CLOT LYSIS; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFICACY; DRUG ELUTING STENT; ELECTROCARDIOGRAPHY; FATALITY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; MORBIDITY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; REVIEW; RISK FACTOR; SAFETY; THROMBOSIS;

CHEMOTHERAPY, ADJUVANT; CORONARY DISEASE; CORONARY THROMBOSIS; DRUG DELIVERY SYSTEMS; FOLLOW-UP STUDIES; HUMANS; PLATELET AGGREGATION INHIBITORS; PROSTHESIS DESIGN; RISK FACTORS; STENTS;

EID: 34347242071     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.04.032     Document Type: Review

References (82)

1. U.S. Food and Drug Association. FDA advises physicians of adverse events associated with Cordis Cypher coronary stents U.S. Food and Drug Administration Public Health Web Notification. Available at: http://www.fda.gov/bbs.topics/ANSWERS/2003/ANS01257.html. Accessed October 29, 2003.
2. Westphal S.P. Concerns prompt some hospitals to pare use of drug-coated stents. Wall Street Journal (2006) A1 June 22
3. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
4. McFadden E.P., Stabile E., Regar E., et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364 (2004) 1519-1521
5. Virmani R., Guagliumi G., Farb A., et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 109 (2004) 701-705
6. Cutlip D.E., Baim D.S., Ho K.K., et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 103 (2001) 1967-1971
7. Finn A.V., Kolodgie F.D., Harnek J., et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 112 (2005) 270-278
8. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans. Delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
9. Moreno R., Fernandez C., Hernandez R., et al. Drug-eluting stent thrombosis results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 45 (2005) 954-959
10. Mauri L., Hsieh W., Massaro J.M., et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
11. U.S. Food and Drug Administration. Circulatory System Devices Panel meeting. December 7-8, 2006. Available at: http://www.fda.gov/ohrms/dockets/ac/cdrh06.html#circulatory. Accessed February 7, 2007.
12. Kastrati A., Mehilli J., Pache J., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
13. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
14. Spaulding C., Daemen J., Boersma E., et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997
15. Lagerqvist B., James S.K., Stenestrand U., et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
16. Curfman G.D., Morrissey S., Jarcho J.A., et al. Drug-eluting coronary stents-promise and uncertainty. N Engl J Med 356 (2007) 1059-1060
17. Holmes Jr. D.R., Holubkov R., Vlietstra R.E., et al. Comparison of complications during percutaneous transluminal coronary angioplasty from 1977 to 1981 and from 1985 to 1986: the National Heart, Lung, and Blood Institute percutaneous transluminal coronary angioplasty registry. J Am Coll Cardiol 12 (1988) 1149-1155
18. Detre K.M., Holmes Jr. D.R., Holubkov R., et al. Incidence and consequences of periprocedural occlusion. The 1985-1986 National Heart, Lung, and Blood Institute percutaneous transluminal coronary angioplasty registry. Circulation 82 (1990) 739-750
19. Kereiakes D.J., Choo J.K., Young J.J., and Broderick T.M. Thrombosis and drug eluting stents: a critical appraisal. Rev Cardiovasc Med 5 (2004) 9-15
20. Ferrari E., Benhamou M., Cerboni P., et al. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 45 (2005) 456-459
21. Karrillon G.J., Morice M.C., Benveniste E., et al. Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy: 30-day clinical outcome of the French Multicenter Registry. Circulation 94 (1996) 1519-1527
22. Moussa I., Mario C.D., Reimers B., et al. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors, and clinical outcome. J Am Coll Cardiol 29 (1997) 6-12
23. Orford J.L., Lennon R., Melby S., et al. Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. J Am Coll Cardiol 40 (2002) 1567-1572
24. Nebeker J.R., Virmani R., Bennett C.L., et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 47 (2006) 175-181
25. Abizaid A., Chan C., Lim Y.T., et al. Twelve-month outcomes with a paclitaxel-eluting stent transitioning from controlled trials to clinical practice (the WISDOM registry). Am J Cardiol 98 (2006) 1028-1032
26. Regar E., Lemos P., Saia F., et al. Incidence of thrombotic stent occlusion during the first three months after sirolimus-eluting stent implantation in 500 consecutive patients. Am J Cardiol 93 (2004) 1271-1275
27. Ong A.T., McFadden E.P., Regar E., de Jaegere P.P., van Domburg R.T., and Serruys P.W. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 45 (2005) 2088-2092
28. Ong A.T., Hoye A., Aoki J., et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 45 (2005) 947-953
29. Wang F., Stouffer G.A., Waxman S., and Uretsky B.F. Late coronary stent thrombosis: early vs. late stent thrombosis in the stent era. Catheter Cardiovasc Interv 55 (2002) 142-147
30. Park D.W., Park S.W., Park K.H., et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 98 (2006) 352-356
31. Bavry A.A., Kumbhani D.J., Helton T.J., and Bhatt D.L. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?. A meta-analysis. J Am Coll Cardiol 45 (2005) 941-946
32. Moreno R., Fernandez C., Calvo L., et al. Risk of stent thrombosis after sirolimus- versus paclitaxel-eluting stents. A meta-analysis from nine randomized trials. (abstr). Circulation 114 Suppl II (2006) II452
33. Kastrati A., Dibra A., Eberle S., et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA 294 (2005) 819-825
34. Stone G. TAXUS RCT meta-analysis and registries, insights and unsettled issues (2006) Presented at: American College of Cardiology Annual Meeting; Atlanta, GA: March 11-14
35. Urban P., Gershlick A.H., Guagliumi G., et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher register. Circulation 113 (2006) 1434-1441
36. Ellis S.G., Colombo A., Grube E., et al. Early and late stent thrombosis after paclitaxel-eluting stents: analysis from the integrated TAXUS randomized trial program. J Am Coll Card 47 Suppl A (2006) 221A
37. Holmes D.R., Moses J.W., Schofer J., et al. Cause of death with bare metal and sirolimus-eluting coronary stents. Eur Heart J 27 (2006) 2815-2822
38. Williams D.O., Abbott J.D., Kip K.E., et al. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover registry. Circulation 114 (2006) 2154-2162
39. Hwang C.W., Levin A.D., Jonas M., et al. Thrombosis modulates arterial drug distribution for drug-eluting stents. Circulation 111 (2005) 1619-1626
40. Spaulding C., Henry P., Teiger E., et al. Sirolimus-eluting stents versus uncoated stents in acute myocardial infarction. N Engl J Med 355 (2006) 1-11
41. Menichelli M. SESAMI: Sirolimus Stent vs Bare Stent in Acute Myocardial Infarction. Available at: http://www.europcronline.com/fo/planning/event/europcr/consult_event.php ?id=491&PHPSESSID=5762b7362f. Accessed December 11, 2006.
42. Laarman G.J., Suttorp M.J., Dirksen M.T., et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 355 (2006) 1105-1113
43. Pfisterer M., Brunner-LaRocca H.P., Buser P.T., et al., BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of the drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
44. Salam A.M., AlSuwaidi J., and Holmes D.R. Drug-eluting coronary stents. Curr Probl Cardiol 31 (2006) 8-119
45. Serruys P.W., Kutryk M.J., and Ong A.T. Coronary artery stents. N Engl J Med 354 (2006) 483-495
46. Farb A., Burke A.P., Kolodgie F.D., and Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 108 (2003) 1701-1706
47. Honda Y., and Fitzgerald P.J. Stent thrombosis: an issue revisited in a changing world. Circulation 108 (2003) 2-5
48. Degetekin M., Serruys P.W., Tanabe K., et al. Long-term follow-up of incomplete stent apposition in patients who received the sirolimus-eluting stent for de novo coronary lesions: an intravascular ultrasound analysis. Circulation 108 (2003) 2747-2750
49. Kotani J., Awata M., Nanto S., et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 47 (2006) 2108-2111
50. Colombo A., Moses J.W., Morice M.C., et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation 109 (2004) 1244-1249
51. Cheneau E., Leborgne L., Mintz G.S., et al. Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound study. Circulation 108 (2003) 43-47
52. Alfonso F., Suarez A., Angiolillo D.J., et al. Findings of intravascular ultrasound during acute stent thrombosis. Heart 90 (2004) 1455-1459
53. Heller L.I., Shemwell K.C., and Hug K. Late stent thrombosis in the absence of prior intracoronary brachytherapy. Catheter Cardiovasc Interv 53 (2001) 23-28
54. Fujii K., Carlier S.G., Mintz G.S., et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation. An intravascular ultrasound study. J Am Coll Cardiol 45 (2005) 995-998
55. Shah V.M., Mintz G.S., Apple S., and Weissman N.J. Background incidence of late malapposition after bare metal stent implantation. Circulation 106 (2002) 1753-1755
56. Moussa I., Di Mario C., Reimers B., et al. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol 29 (1997) 6-12
57. Grines C.L., Bonow R.O., Casey D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 49 (2007) 734-739
58. Spertus J.A., Kettelkamp R., Vance C., et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113 (2006) 2803-2809
59. Morici N., Airoldi F., Briguori C., et al. Relationship of occurrence of drug-eluting stent thrombosis and assumption of double antiplatelet therapy. Am J Cardiol 98 (2006) 8M
60. Eisenstein E.L., Anstrom D.J., Kong D.F., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantationl. JAMA 297 (2007) 480-488
61. Harrington R.A., and Califf R.M. Late ischemic events after clopidogrel cessation following drug-eluting stenting. Should we be worried?. J Am Coll Cardiol 48 (2006) 2592-2595
62. Kereiakes D.J. Does clopidogrel each day keep thrombosis away?. The evolving therapeutic algorithm for drug-eluting stents. JAMA 297 (2007) 209-211
63. Morice M.C., Serruys P.W., Sousa J.E., et al., RAVEL Study Group. Randomized study with the sirolimus-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
64. Serruys P.W., Ong A.T., Morice M.C., et al. Arterial revascularization therapies part II-sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions. Eurointervention 2 (2005) 147-156
65. Siqueira D.A., Abizaid A., Feres F., et al. Late-acquired incomplete apposition after drug-eluting stents: frequency and potential for late stent thrombosis. (abstr). J Am Coll Cardiol 365 Suppl A (2006) 365A
66. Mintz G.S., and Weissman N.J. Intravascular ultrasound in the drug-eluting stent era. J Am Coll Cardiol 48 (2006) 421-429
67. Hoye A., Iakovou I., Ge L., et al. Long-term outcomes after stenting of bifurcation lesions with the "crush" technique: predictors of an adverse outcome. J Am Coll Cardiol 47 (2006) 1949-1958
68. Meredith I.T., Ormiston J., Whitbourn R., et al. First-in-human study of the Endeavor ABT-578-eluting phophorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I trial. Eurointervention 1 (2005) 157-164
69. Lee S.-W., Park S.-W., Hong M.-K., et al. Triple versus dual antiplatelet therapy after coronary stenting. impact on stent thrombosis. J Am Coll Cardiol 46 (2005) 1833-1837
70. Smith SC Jr., Feldman TE, Hirshfeld JW Jr., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. Available at: http://www.acc.org/qualityandscience/clinical/guidelines/percutaneous/up date/index.pdf.
71. Daemen J., and Serruys P.W. Drug-eluting stent update 2006-part 1: device overview, current clinical results and unsettled issues. Circulation (2007) In press
72. Aoki J., Serruys P.W., van Beusekom H., et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) registry. J Am Coll Cardiol 45 (2005) 1574-1579
73. Erbel R, Bonnier J, Koolen C. Coronary results of the first absorbable metal stent: the PROGRESS-I trial. Available at: http://acc06online.acc.org/Lectures.aspx?sessionID=92&date=13. Accessed December 11, 2006.
74. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 55 (2006) 780-784
75. Holmes D.R. Antiplatelet therapy after percutaneous coronary intervention (PCI). Cerebrovasc Dis 21 (2006) 25-34 S1
76. Serebruany V.L., Steinhubl S.R., Berger P.B., et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45 (2005) 246-251
77. Lev E.I., Patel R.T., Maresh K.J., et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 47 (2006) 27-33
78. Matetzky S., Shenkman B., Guetta V., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004) 3171-3175
79. Michelson A.D., Cattaneo M., Eikelboom J.W., et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 3 (2005) 1309-1311
80. Patti G., Colonna G., Pasceri V., et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty) study. Circulation 111 (2005) 2099-2106
81. Wiviott S.D., Antman E.M., Winters K.J., et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 111 (2005) 3366-3373
82. van Giezen J.J., and Humpries R.G. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost 31 (2005) 195-209